Fluidigm Corp.
Fluidigm Corp. is listed today as Standard BioTools Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2014 | $77 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jan 2011 | $5 M | No. 3 | $2 to $10 million | debt, options | SEC | |
| Nov 2009 | $19 M | No. 2 | $10 to $50 million | equity | SEC | |
| Aug 2009 | $11 M | No. 1 | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Standard BioTools Inc., its revenue in fiscal 2025 came from these product and service lines: Consumables $36.25 million (42%), Instruments $25.41 million (30%), Services and other revenue $23.67 million (28%), Services and other revenue $23.67 million (28%).
Annual report (SEC XBRL) · Dec 2025
Fluidigm Corp. chose not to state its revenue in its newest notice of a funding round (Feb 2014).
SEC Form D · Feb 2014
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2014
Products and services#
No products or services of Fluidigm Corp. are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Biomedical Sciences Investment Fund Pte Ltd. | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| EDB Investments Pte Ltd. | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| EuclidSR Biotechnology Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| EuclidSR Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Singapore Bio Innovations Pte LTD | Company | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Versant Affiliates Fund I-A LP | Fund or asset manager | not stated | not stated | Held Series B, C, D, E and E1 preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Versant Affiliates Fund I-B LP | Fund or asset manager | not stated | not stated | Held Series B, C, D, E and E1 preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Versant Side Fund I LP | Fund or asset manager | not stated | not stated | Held Series B, C, D, E and E1 preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Versant Venture Capital I LP | Venture capital | not stated | not stated | Held Series B, C, D, E and E1 preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 101 investors.
Largest shareholders today
Institutions holding Standard BioTools Inc. shares, as of Sep 30, 2026.
- Casdin Capital, LLC$66 M22.49%
- Viking Global Investors LP$43 M14.86%
- Long Focus Capital Management, LLC$19 M6.41%
- Mak Capital One LLC$18 M6.33%
- Vanguard Capital Management LLC$9 M3.17%
- BlackRock, Inc.$6 M2.09%
- Hollow Brook Wealth Management LLC$4 M1.32%
- Qube Research & Technologies Ltd$4 M1.25%
- Neuberger Berman Group LLC$3 M1.10%
- D. E. Shaw & Co., Inc.$3 M1.02%
- Geode Capital Management, LLC$3 M0.90%
- Tikvah Management LLC$3 M0.90%
- Arrowstreet Capital, Limited Partnership$2 M0.85%
- Gsa Capital Partners LLP$2 M0.77%
- Morgan Stanley$2 M0.70%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Fred C. Walder | Executive officer | Feb 2014 |
| Gajus V. Worthington | Executive officer | Feb 2014 |
| Grace M. Yow | Executive officer | Feb 2014 |
| Robert C. Jones | Executive officer | Feb 2014 |
| Vikram A. Jog | Executive officer | Feb 2014 |
| William M. Smith | Executive officer | Feb 2014 |
| Fredric C. Walder | Executive officer | Jan 2011 |
| Mai Chan C. Yow | Executive officer | Jan 2011 |
| Vikram V. Jog | Executive officer | Jan 2011 |
| Vikram W. Jog | Executive officer | Nov 2009 |
| Mai Chan Yow | Executive officer | Aug 2009 |
| Vikram Jog | Executive officer | Aug 2009 |
| Evan F. Jones | Director | Feb 2014 |
| Gajus V. Worthington | Director | Feb 2014 |
| Gerhard F. Burbach | Director | Feb 2014 |
| John A. Young | Director | Feb 2014 |
| Patrick S. Jones | Director | Feb 2014 |
| Samuel D. Colella | Director | Feb 2014 |
| Jeremy D. Loh | Director | Jan 2011 |
| Kenneth J. Nussbacher | Director | Jan 2011 |
| Raymond I. Whitaker | Director | Jan 2011 |
| John M. Young | Director | Nov 2009 |
| Lawrence J. Chin | Director | Nov 2009 |
| Michael W. Hunkapiller | Director | Nov 2009 |
| Raymond V. Whitaker | Director | Nov 2009 |
| Samuel W. Colella | Director | Nov 2009 |
| John Young | Director | Aug 2009 |
| Kenneth Nussbacher | Director | Aug 2009 |
| Michael Hunkapiller | Director | Aug 2009 |
| Raymond Whitaker | Director | Aug 2009 |
| Samuel Colella | Director | Aug 2009 |
Went public since 2011. Its SEC number is that of a company listed on a stock exchange.